Will Rx IB deal flow surge given the current macroeconomic environment?

I was wondering if anyone had any knowledge around Rx deal flow this year. More specifically, is it growing and do you believe that Rx may be better positioned than M&A, ECM, and DCM over the next 2-3 years or so. Thanks for any input.

Comments (1)

12d 
UBS ate CS, what's your opinion? Comment below:

Aspernatur eos aspernatur incidunt qui. Voluptatum optio reprehenderit accusantium ut a commodi. Adipisci non est dolores et. Non nostrum exercitationem quaerat et sunt beatae esse mollitia.

Start Discussion

Career Advancement Opportunities

March 2023 Investment Banking

  • Lazard Freres (+ +) 99.5%
  • Lincoln International (= =) 99.1%
  • Jefferies & Company (▽02) 98.6%
  • Financial Technology Partners (▽01) 98.2%
  • William Blair (▲11) 97.7%

Overall Employee Satisfaction

March 2023 Investment Banking

  • William Blair (▲05) 99.5%
  • Lincoln International (▲11) 99.1%
  • Canaccord Genuity (▲17) 98.6%
  • Stephens Inc (▲10) 98.1%
  • Financial Technology Partners (▲04) 97.7%

Professional Growth Opportunities

March 2023 Investment Banking

  • Financial Technology Partners (▲05) 99.5%
  • Lincoln International (▲01) 99.1%
  • Lazard Freres (▲14) 98.6%
  • Jefferies & Company (▽03) 98.2%
  • William Blair (▲03) 97.7%

Total Avg Compensation

March 2023 Investment Banking

  • Director/MD (6) $592
  • Vice President (27) $425
  • Associates (141) $260
  • 3rd+ Year Analyst (9) $194
  • 2nd Year Analyst (86) $170
  • 1st Year Analyst (266) $170
  • Intern/Summer Associate (45) $165
  • Intern/Summer Analyst (195) $92